Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...

Whoop is whooping it up with a massive $575 million raise amid a strong start to the year for the fitness wearable.  | Whoop ...

After emerging from stealth last month with $175 million, Korsana Biosciences has wasted no time in plotting a path to the ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of ...

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...

Bristol Myers Squibb has tapped up Faro to use AI to improve the Big Pharma's clinical trial protocols. | Bristol Myers ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...